Lexeo TherapeuticsLXEO
LXEO
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
263% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 8
142% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 12
30% more funds holding
Funds holding: 69 [Q3] → 90 (+21) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
0.98% less ownership
Funds ownership: 90.24% [Q3] → 89.26% (-0.98%) [Q4]
28% less capital invested
Capital invested by funds: $270M [Q3] → $194M (-$75.5M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$18
492%
upside
Avg. target
$22
607%
upside
High target
$25
722%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor 33% 1-year accuracy 59 / 181 met price target | 657%upside $23 | Buy Reiterated | 26 Mar 2025 |
RBC Capital Luca Issi 22% 1-year accuracy 12 / 55 met price target | 558%upside $20 | Outperform Maintained | 25 Mar 2025 |
Chardan Capital Geulah Livshits 10% 1-year accuracy 6 / 58 met price target | 722%upside $25 | Buy Maintained | 25 Mar 2025 |
Leerink Partners Mani Foroohar 33% 1-year accuracy 5 / 15 met price target | 492%upside $18 | Outperform Maintained | 24 Mar 2025 |
Financial journalist opinion
Negative
MarketBeat
1 week ago
Pharma Frenzy: Volatility Ignites Biotech Sector
The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price surges in Tonix Pharmaceuticals NASDAQ: TNXP and Lexeo Therapeutics NASDAQ: LXEO. The biotech industry is known for its volatile price swings, often influenced by clinical trial results and regulatory decisions.
Neutral
GlobeNewsWire
1 week ago
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, frataxin expression to be evaluated for any increase from baseline rather than numerical threshold Interim update from cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial: observed 71% and 115% increases in PKP2 protein expression in first two post-treatment biopsies; first participant evaluated 6-months after dosing experienced 67% reduction in premature ventricular contractions (PVCs) Completed enrollment of cohort 2 of LX2020 HEROIC-PKP2 Phase 1/2 trial; interim clinical data update expected in second half of 2025 LX2020 has been generally well tolerated with no treatment-related serious adverse events to date Cash, cash equivalents and investments of $128.5 million expected to provide operational runway into 2027 NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported fourth quarter and full year 2024 financial results. “We are pleased to share further regulatory clarity for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, and we appreciate the continued partnership from the FDA on an accelerated approval pathway to support adults and children living with this devastating condition,” said R.
Neutral
GlobeNewsWire
2 months ago
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 43rd Annual J.P.
Neutral
GlobeNewsWire
3 months ago
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs.
Neutral
GlobeNewsWire
4 months ago
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial; initial clinical data including safety and biodistribution on track for late Q1 / early Q2 2025 Appointed Tolga Tanguler to Board of Directors, an accomplished biopharmaceutical executive with over 25 years of senior leadership experience Cash and cash equivalents of $157.0 million expected to provide operational runway into 2027 NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today provided business updates across its portfolio of programs and reported third quarter 2024 financial results. “We have made significant progress over the last few months across all our clinical stage programs, including reaching alignment with the FDA on registrational endpoints to support an accelerated approval pathway for LX2006.
Neutral
GlobeNewsWire
5 months ago
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's
Neutral
GlobeNewsWire
5 months ago
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that interim data from the ongoing Phase 1/2 trial (NCT03634007) of LX1001 have been selected as a late-breaking oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference taking place October 29 - November 1, 2024, in Madrid, Spain. The presentation will include new safety and biomarker data from four dose cohorts of LX1001, an AAVrh10-based gene therapy candidate designed to deliver the protective APOE2 gene into the central nervous systems of APOE4 homozygotes with Alzheimer's disease.
Neutral
GlobeNewsWire
6 months ago
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences: H.C.
Neutral
GlobeNewsWire
7 months ago
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures
Positive
Seeking Alpha
8 months ago
Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Lexeo Therapeutics, Inc. achieved positive results across two studies using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy; Clinically meaningful improvements observed in several cardiac biomarkers. The global Friedreich's ataxia market is expected to reach $3.39 billion by 2034. Additional interim results, along with cardiac biopsy assessment in FA patients with LX2006, expected at an upcoming medical conference presentation in Fall of 2024.
Charts implemented using Lightweight Charts™